comparemela.com
Home
Live Updates
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC : comparemela.com
FDA Staff Highly Skeptical of Confirmatory Data on KRAS Inhibitor in NSCLC
Reviewers see potentially tiny PFS benefit with sotorasib, raise concerns over 'systemic bias'
Related Keywords
,
Oncologic Drugs Advisory Committee ,
Oncologic Drugs Advisory Committee On ,
Managing Editor ,
Medpage Today ,
comparemela.com © 2020. All Rights Reserved.